OncoMatch/Clinical Trials/NCT05345613
Tranexamic Acid During Colonic Endoscopic Resection Procedures
Is NCT05345613 recruiting? Yes, currently enrolling (Sep 2026). This Phase 4 trial studies multiple treatments including Tranexamic acid and Standard for colon neoplasm.
Treatment: Tranexamic acid · Standard — Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05345613 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages